期刊文献+

PSA、PSAD、PSAT在前列腺偶发癌诊断中的的意义

The significance of serum prostate specific antigen prostate specific antigen density and density of the transition zone in incidental adenocarcinoma of prostate
下载PDF
导出
摘要 目的 探讨血清前列腺特异性抗原 (PSA)及其密度 (PSAD)和移行带密度 (PSAT)在前列腺偶发癌诊断中的意义。方法 选择经手术证实的前列腺偶发癌患者 2 7例和前列腺增生症 (BPH)患者 3 2例 ,比较其 PSA、PSAD、PSAT指标。结果 前列腺偶发癌组和 BPH组 PSA分别为 (5 .0 3± 1 .61 )、(4 .3 1± 1 .5 2 ) μg/ L,差异无显著性 (P >0 .0 5 ) ;PSAD分别为 (0 .1 7± 0 .1 6)、(0 .0 9± 0 .1 3 )μg/ L ,差异有显著性 (P <0 .0 5 ) ;PSAT分别为 (0 .2 9± 0 .1 0 )、(0 .1 5± 0 .1 6) μg/ L,差异具有非常显著性 (P <0 .0 1 )。结论 PSAD、PSAT对前列腺偶发癌的诊断具有重要价值 ,其中尤以 PSAT更具预测价值。 Objective To define the role of serum prostate specific antigen(PSA),PSA density(PSAD) and PSA density of the transition zone(PSAT) in incidental adenocarcinoma of prostate.Methods The data of 27 patients with incidental adenocarcinoma of prostate and 32 patients with BPH were collected,then compared PSA,PSAD,PSAT between the two groups.Results The mean PSA in incidental adenocarcinoma of prostate group and BPH group were(5.03±1.61) and(4.31±1.52) ,respectively ,with no statistic difference( P <0.01). The mean PSAD in incidental adenocarcinoma of prostate group and BPH group were (0.17±0.16) and(0.09±0.13) respectively with statistic difference( P <0.05). The mean PSAT in incidental adenocarcinoma of prostate group and BPH group were(0.29±0.10) and(0.15±0.16) respectively with obviously statistic difference( P <0.01).Conclusions The result suggest PSAD,PSAT could be used to distinguish incidental adenocarcinoma of prostate and BPH.
出处 《医学文选》 2004年第5期569-571,共3页 Anthology of Medicine
关键词 前列腺增生症 前列腺偶发癌 前列腺特异性抗原密度 前列腺移行区特异性抗原密度 Benign ptostatic hyperplasia Incidental adenocarcinoma of prostate Prostate specific antigen density Prostate specific antigen density of transition zone.
  • 相关文献

参考文献10

  • 1[1]Van Andel G, Vleeming R, Kurth K, etal. Incidental carcinoma of the prostate[J].Semin Surg Oncol. 1995, 11(1):36~45.
  • 2戴波,叶定伟.前列腺偶发癌[J].国外医学(泌尿系统分册),2003,23(5):494-497. 被引量:4
  • 3[3]Benson MC, Whang IS, Olsson CA,J etal. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen[J]. Urol,1992,147(3):817~821
  • 4[4]Djavan B, Zlotta AR, Remzi M, etal. Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?[J].Urology,1999,54(5):846~852
  • 5[5]Djavan B, Zlotta A, Kratzik C, etal. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL[J]. Urology,1999,54(3):517~522
  • 6[6]Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients[J].J Urol,1989,141(5):1076~1083
  • 7[7]Benson MC,Whang lS,Pantuek A,etal.Prostate specific antigen density: a means of distinguishing benign prostatie by pertrophy and prostate cancer[J]. J Urol,1992,147(3):815~816
  • 8[8]McNeal JE.The prostate gland:morphology and pathobiology[J].Monogr Urol, 1988,9(6):36~54
  • 9[9]Kalish J, Cooner WH, Graham SD.Serum PSA adjusted for volume of transition zone (PSAT) is more accurate thanPSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate[J]. Urology,1994 ,43(5):601~606
  • 10[10]Kurita Y, Suzuki A, Masuda H, etal. Transition zone volume-adjusted prostate-specific antigen value predicts extracapsular carcinoma of the prostate in patients with intermediate prostate-specific antigen levels[J].Eur Urol,1998,33(1):32~38

二级参考文献16

  • 1Bostwick DG.Far Urol,1997;32 (Suppl 3):2 - 14.
  • 2van Andel G, Vleeming R, Kurth K, et al. Semin Surg Oncol, 1995; 11:36-45
  • 3Brendler CB. Urology, 1995 ;46(3 Suppl A) :71 - 76.
  • 4Kitamura H, Mastanori N,Tanuma Y,et al. Int J Urol,2002;9:95 - 99.
  • 5Hayakawa T,Mitsuya H, Kojima M,et al.Hinyokika Kiyo,2002;48:13 -16.
  • 6Sandblom G, Dufmats M, Notdenskjold K,et al. Cancer,2000; 88:1445 -1453.
  • 7Lowe FC.Urulogy,2002;59(2 Suppl 1) : 1 - 2.
  • 8Wu TT, Huang JK. BJU Int,2001 ;87:57 - 60.
  • 9Mai KT, Isotalo PA, Gteen J, et al. Arch Pathol Lab Med, 2000;124:1454-1456.
  • 10Murphy WM, Dean PJ, Brasfield JA, et al. Am J Surg Pathol, 1986; 10:170- 174.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部